Report Type: Therapy Reports
Report Category: Women's Health
Report Subcategory: Premenstrual Dysphoric Disorder or PMDD
Price: $2999.00
Date: January 2022

Premenstrual Dysphoric Disorder or PMDD: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Premenstrual Dysphoric Disorder or PMDD
Premenstrual dysphoric disorder (PMDD) is a severe form of PMS that includes physical and behavioural symptoms that usually resolve with the onset of menstruation causes extreme mood shifts.

Top 10 Companies:
Pfizer Inc
Bayer AG
GlaxoSmithKline Plc
Eli Lilly and Co
Aspen Pharmacare Holdings Ltd
Apotex Inc
Rena Science Co Ltd
Umecrine AB
Pherin Pharmaceuticals Inc
MetVital Inc